Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Box: Knocking out or knocking down

    Modeling with interference Tools & Techniques Knocking out or knocking down CRISPRi's tunable and reversible gene knockdown makes it an ideal tool for modifications in induced pluripotent stem (iPS) cells, but it …

    Published on 5/12/2016
  • Figure: CRISPRi: Technological knockdown

    Modeling with interference Tools & Techniques CRISPRi: Technological knockdown In a new study in Cell Stem Cell, a group of University of California San Francisco researchers described how to use CRISPR …

    Published on 5/12/2016
  • Figure: As easy as 1, 2, 3, 4...

    Cell therapy's yada yada yada Product R&D As easy as 1, 2, 3, 4... Manufacturing of allogeneic and autologous cells involves seven basic steps before a patient can receive them. (1) Apheresis. Blood is drawn from …

    Published on 5/5/2016
  • Cell therapy's yada yada yada

    Challenges and solutions for GMP manufacturing of cell therapies

    Despite the scientific advances of cell therapy, the less glamorous innovations in manufacturing could be the difference-maker for translational and commercial success.

    Published on 5/5/2016
  • Figure: Measuring acceleration

    Virtually biotechs Finance Measuring acceleration Licensing revenue is often considered a key metric for tracking success of technology transfer offices (TTOs). For universities that are adopting the virtual …

    Published on 4/28/2016
  • Virtually biotechs

    Why early stage academic deals are heating up

    While the $20 million Harvard-Merck licensing deal is unlikely to be matched in size any time soon, it might reflect a growing translational savviness in academia.

    Published on 4/28/2016
  • On the road

    Nine challenges FDA wants scientists to solve for NGS-based diagnostics

    FDA has responded to the explosion of interest in next-generation sequencing for precision diagnostics with a roadmap for solving the big regulatory challenges.

    Published on 4/21/2016
  • Figure: Next year in the clinic...

    On the road Tools & Techniques Next year in the clinic... In a Perspective in Science Translational Medicine, FDA outlined nine informatics research areas to advance regulatory evaluation of next-generation …

    Published on 4/21/2016
  • Next stop: Houston

    How JLABS' new site at TMC plays into Houston's hub hopes

    While JLABS' new site at the Texas Medical Center is a welcome investment in the region, Houston is still in the early days of its quest to become the next U.S. biotech hub.

    Published on 4/14/2016
  • Figure: Companies formed

    Next stop: Houston Strategy Companies formed Total number of new biopharma companies formed in multiple regions of the U.S. from 2010 to 2016. Source: BCIQ: BioCentury Online Intelligence

    Published on 4/14/2016
  • Figure: Seed and series A funding

    Next stop: Houston: Figure: Seed and series A funding Next stop: Houston Strategy Seed and series A funding Seed and series A funding amounts for each region from 2010 to 2016. Total values include all disclosed …

    Published on 4/14/2016
  • Figure: Tri-coastal Spread

    Next stop: Houston Strategy Tri-coastal Spread Total National Institutes of Health (NIH) funding for select academic institutions in the San Francisco Bay Area (blue); Boston and Cambridge, Mass. (green); and …

    Published on 4/14/2016
  • Table: Homing to Houston

    Next stop: Houston Strategy Homing to Houston Founding companies in the JLABS @ TMC incubator at the Texas Medical Center (TMC) focused on therapeutics and diagnostics. The table does not include companies focused …

    Published on 4/14/2016
  • Figure: Molecules to Mimic

    Branching out Product R&D Molecules to Mimic

    Published on 4/7/2016
  • Table: Biocentury Product Profile

    Branching out Product R&D Biocentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Peptide-based proteoglycan mimetics Concept Synthetic compounds that mimic endogenous proteoglycans to …

    Published on 4/7/2016
  • Branching out

    Symic's proteoglycan mimetics branch out

    Symic believes its proteoglycan mimetics can work in multiple indications, and has added new preclinical programs in fibrosis, oncology and CNS disorders.

    Published on 4/7/2016
  • Table: BioCentury Product Profile

    Shrinking reservoirs Tools & Techniques BioCentury Product Profile Biocentury Product Profile INNOVATION STAGE Product A recombinase or CRISPR-based gene-editing system that excises HIV provirus by targeting the…

    Published on 3/31/2016
  • Shrinking reservoirs

    Why attacking HIV reservoirs is a tall order

    Using an engineered recombinase or CRISPR to snip out the HIV genome, two groups think they can eliminate viral reservoirs. Reaching every cell will be the problem.

    Published on 3/31/2016
  • Figure: Coordinated attack

    Combo platter Strategy Coordinated attack Incyte Corp. (NASDAQ:INCY) is taking a pathway-based approach to building its pipeline by selecting targets that yield coordinated benefit if attacked simultaneously. The …

    Published on 3/24/2016
  • Figure: Mix and match

    Combo platter Strategy Mix and match Incyte Corp. (NASDAQ:INCY) is building a portfolio of anticancer compounds designed to have maximal synergies with each other. With the March announcement of its OX40-targeted …

    Published on 3/24/2016
  • Combo platter

    How Incyte aims to discover high synergy combo therapies

    Instead of playing catch-up to find cancer combos once molecules reach the clinic, Incyte is building combo-thinking into its preclinical strategy from the outset.

    Published on 3/24/2016
  • Transcending TransCelerate

    TransCelerate's preclinical move into toxicology

    TransCelerate has created the subsidiary BioCelerate to expand its reach into the preclinical space, starting with toxicology.

    Published on 3/17/2016
  • Table: Toxicology data initiatives

    Transcending TransCelerate Strategy Toxicology data initiatives Selected toxicology-centered consortia with large data-sharing components. Although several older groups are already well established, BioCelerate …

    Published on 3/17/2016
  • Box: Questioning UCP1

    Brown fat heats up Targets & Mechanisms Questioning UCP1 While there is evidence that manipulating targets such as FGF21, USF1 and SLIT2 promote both metabolic benefits and brown fat activity, it is still not clear…

    Published on 3/10/2016
  • Figure: Feel the burn

    Brown fat heats up Targets & Mechanisms Feel the burn Three studies have identified new molecular targets to treat obesity and metabolic diseases by enhancing thermogenesis - a process in which brown or beige …

    Published on 3/10/2016

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993